EDIT vs VRTX · rev $32.3M vs P/E 30, rev $12.00B
Editas Medicine Inc (EDIT) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
EDIT currently screens at market cap $375.2M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the EDIT and VRTX stock pages for the full models.
Not investment advice.